Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Non-malignant811 active trials6 approved drugs154 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Clinical trials
2,935 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07145047 | Clinical Study of Oncolytic Virus in Glioblastoma | recruiting | Phase 1 / Phase 2 | 20 | Mianyang Central HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04543201 |
| Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma |
| recruiting |
| N/A |
| 50 |
| University of RochesterOTHER |
| 1 |
| Dec 18, 2025 |
| clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT05976490 | NeuroPathways Intervention for Brain Tumor Patients | recruiting | N/A | 50 | Massachusetts General HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | recruiting | Phase 1 | 18 | Henry Ford Health SystemOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285525 | Accelerating Motor Recovery in Glioma Patients Using Postoperative nrTMS | active not recruiting | N/A | 43 | Beijing Neurosurgical InstituteOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286903 | Fluorescence Enhanced Stereotactic Surgery (FESS)(FESS) | recruiting | — | 20 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07286929 | Evaluation of the Variation Over Time of Visuospatial Deficit in Patients With Parietal Lobe Glioma(neGLIO) | recruiting | — | 40 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | active not recruiting | Early Phase 1 | 14 | Emory UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT01358058 | Proton Radiation Therapy for Gliomas | active not recruiting | N/A | 63 | Massachusetts General HospitalOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07077616 | Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.(TAMAVAQTM) | recruiting | Early Phase 1 | 29 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03212742 | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients(OLA-TMZ-RTE-01) | active not recruiting | Phase 1 / Phase 2 | 91 | Centre Francois BaclesseOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05553041 | 18F-Fluciclovine PET-MRI in High-grade Glioma | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06227962 | Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors(RbNeuroQoL) | enrolling by invitation | — | 240 | Amsterdam University Medical CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263711 | Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction | recruiting | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06209567 | A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors | active not recruiting | Early Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05990244 | Magnetic Resonance Elastography in Glioma: Exploring Tumor Stiffness and Adhesion | recruiting | N/A | 100 | Shengjing HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06964815 | Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients(STRONG) | recruiting | N/A | 110 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04681417 | Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome(RETINO 2018) | recruiting | Phase 2 / Phase 3 | 225 | Institut CurieOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT03687957 | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide | active not recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02866136 | Conservative Treatments of Retinoblastoma(RETINO2011) | active not recruiting | Phase 2 | 133 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03718767 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | active not recruiting | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07244666 | Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma | not yet recruiting | Early Phase 1 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04945148 | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide(OPTIMUM) | recruiting | Phase 2 | 640 | Hopital FochOTHER | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06930846 | HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)(HOBSCOTCH-CA) | recruiting | N/A | 125 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT04299191 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 28 | Laminar PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | active not recruiting | Phase 1 | 72 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06072586 | A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions | recruiting | Early Phase 1 | 82 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07164053 | Evaluation of Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes.(IMED-MYVEO) | not yet recruiting | — | 32 | Leica Microsystems (Schweiz) AGINDUSTRY | 2 | Nov 20, 2025 | clinicaltrials |
| NCT07211841 | Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)(GLIOMIT) | not yet recruiting | N/A | 30 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT07193628 | B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma | recruiting | Phase 1 | 14 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05045027 | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | active not recruiting | Early Phase 1 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT06090903 | Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma | recruiting | N/A | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05717153 | Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma | recruiting | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04319276 | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma | active not recruiting | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT06455605 | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | recruiting | Phase 1 | 46 | Darell BignerOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04373785 | NG101m Adjuvant Therapy in Glioblastoma Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | NeuGATE TheranosticsINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT03101813 | International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository | recruiting | — | 1,500 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Oct 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 19, 2025source: clinicaltrials